Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Lennon
CYMI - 200 TABLETS CYMI - 400 TABLETS SCHEDULING STATUS: S3 PROPRIETARY NAME: (and dosage form) CYMI - 200 TABLETS CYMI - 400 TABLETS COMPOSITION: Each tablet contains 200 mg or 400 mg cimetidine respectively. PHARMACOLOGICAL CLASSIFICATION: A 11.4.3 Medicines acting on the gastro-intestinal tract Other PHARMACOLOGICAL ACTION: Cimetidine is a histamine H2-receptor antagonist. Its main action is to inhibit gastric acid secretion. It also inhibits competitively the other actions of histamine mediated by H2-receptors. The decrease in gastric acid secretion occurs regardless of the nature of the physiological stimulus to secretion, i.e. basal or unstimulated secretion, is reduced. Both the volume of secretion and the concentration of acid in the secretion are reduced. INDICATIONS: The treatment of benign gastric and duodenal ulcers, reflux oesophagitis, Zollinger-Ellison syndrome and in other conditions associated with gastric hypersecretory states, such as systemic mastocytosis and multiple endocrine adenomas. It is also indicated at reduced dosage for duodenal ulcer recurrence in selected patients. CONTRA-INDICATIONS: Cimetidine is not recommended for minor digestive complaints. It is also not recommended for patients with impaired renal function. DOSAGE AND DIRECTIONS FOR USE: Clinical experience with cimetidine in children is limited. Therefore cimetidine therapy cannot be recommended in children. Treatment should be continued for at least 4 weeks. Duodenal ulcer: 400 mg twice daily and at bedtime, or 800 mg at bedtime. Maintenance dose for recurrent duodenal ulcer: One 400 mg tablet at bedtime. Benign active gastric ulceration: The usual preferred dose is 200 mg three times a day with meals and 400 mg at bedtime. Alternatively 400 mg at breakfast with 400 mg at bedtime or a dail Read the complete document